Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the treatment of Melanoma. By clicking the button below you are declaring and confirming that you are a healthcare professional.

FREE ACCESS TO THE LATEST RESEARCH


Welcome to the European Journal of Cancer’s Advances in Melanoma Resource Centre.

The Resource Centre, edited by Prof. Reinhard Dummer, Dr. Paolo Ascierto and Dr. James Larkin, will provide you with the latest research on melanoma, including a selection of original research and review articles from some of the world’s leading journals, case studies, and other educational material.

New articles will be added to the Resource Centre regularly and are openly available to our readers.

Paper of the month – October 2014

  • eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies

    Lise Boussemart, Hélène Malka-Mahieu, Isabelle Girault, Delphine Allard, Oskar Hemmingsson, Gorana Tomasic, Marina Thomas, Christine Basmadjian, Nigel Ribeiro, Frédéric Thuaud, Christina Mateus, Emilie Routier, Nyam Kamsu-Kom, Sandrine Agoussi, Alexander

    Nature 513, 105–109 (04 September 2014) doi:10.1038/nature13572

    Editorial comment by professor Reinhard G. Dummer:
    A French research group headed by Dr. Vagner has investigated molecular alterations associated drug resistance in V600E mutated tumor cells treated with targeted therapies. The eIF4F translation initiation complex was identified as  a central intersection node  to generate resistance against B raf inhibitors. and MEK inhibitors as well as the combination of both. This complex, that is a key regulator of mRNA translation, is a central mechanism of resistance in melanoma and also in other cancer types such as colon and thyroid cancers. Interestingly, an in-situ test system was developed to demonstrate the functioning of this pathway in human tumor tissue.


Latest articles

  • Systemic treatment for BRAF-mutant melanoma: where do we go next?

    Alexander M Menzies, Georgina V Long

    Review Article The Lancet Oncology, Volume 15, Issue 9, August 2014, Pages e371-e381
  • AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment.

    Caputo E, Miceli R, Motti M, Taté R, Fratangelo F, Botti G, Mozzillo N, Carriero M, Cavalcanti E, Palmieri G, Ciliberto G, Pirozzi G, Ascierto P.

    J Transl Med. 2014 Jul 31;12(1):216. [Epub ahead of print]

    Editor's comments:
    In this work it was explored the effect of a triple combination with BRAF and MEK inhibitors together with an Aurora kinase A inhibitor, on a melanoma cell line in a 3D human skin model. For the first time it was observed that BRAF, MEK and AurkA inhibitor triple drug combination may increased efficacy against melanoma cell growth and could be potentially explored in a clinical trial for enhancing clinical response in melanoma

  • The immune-related role of BRAF in melanoma

    Sara Tomei, Davide Bedognetti, Valeria De Giorgi, Michele Sommariva, Sara Civini, Jennifer Reinboth, Muna Al Hashmi, Maria Libera Ascierto, Qiuzhen Liu, Ben D. Ayotte, Andrea Worschech, Lorenzo Uccellini, Paolo A. Ascierto, David Stroncek, Giuseppe Palmie

    Original Research Article Molecular Oncology, In Press, Uncorrected Proof, Available online 6 August 2014

    Editor's comments:
    The role of oncogenes BRAF and NRAS has been extensively described with regard to their ability to promote tumor growth. It is not yet clear their role to influence the modulation of the immune response against the tumor. In this study it was investigated the correlation between the presence NRAS or BRAF mutation, the gene expression profile and the presence of one of the two different immune phenotypes, the Th17 and the Th1, which were previously connected to different classes of prognosis. According to this study, the BRAF mutation was associated with a worse prognosis immunophenotype, while there was no clear correlation between the mutation of NRAS and the context of tumor immunology. Despite the great interest of these results, it remains unclear what are the mechanisms that underlie this association and what are the possible clinical implications.


About the editors


Share

 

 

E-Alert

Register to our E-Alert to stay informed of new clinical research and cases published on this platform.

Event planner

Featured videos

Watch the videos from Reinhard Dummer, Dirk Schadendorf, Veronique del Marmol and Christian Blank.

Search this site

Search form

EJC SOCIETY PARTNERS